|
WO2020109506A1
|
|
Mitochondrial activity inhibitors targeting tumoral metabolism
|
|
AU2019334676A1
|
|
Herv-K-derived antigens as shared tumor antigens for anti-cancer vaccine
|
|
AU2018205730A1
|
|
Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
|
|
CN110234640A
|
|
Benzimidizole derivatives as anticancer agent
|
|
EP3422003A1
|
|
Method for determining if a patient is at risk of having or developing a colorectal cancer (crc)
|
|
WO2017207690A1
|
|
Prognostic relevance of mir-422a in head and neck squamous cell carcinoma
|
|
US2020232974A1
|
|
Lymphocytes expressing cd73 in cancerous patient dictates therapy
|
|
EP3321362A1
|
|
Tlr3 agonist for use for inducing apoptosis in senescent cancer cells
|
|
FR3037403A1
|
|
Method for predicting susceptibility of gastrointestinal tumor to inhibitory treatment
|
|
FR3028955A1
|
|
Method for predicting the sensitivity of a patient to inhibitory treatment of the mtor path
|
|
FR3016372A1
|
|
Process for the preparation of induced pluripotent cells
|
|
AU2012233652A1
|
|
Antibodies directed against ICOS and uses thereof
|
